Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?

Pistolesi D, Giannarini G, Stampacchia G, Selli C.

Eur Urol. 2011 Oct;60(4):872-3. doi: 10.1016/j.eururo.2011.07.034. Epub 2011 Jul 19. No abstract available.

PMID:
21802198
2.

Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity.

Gomes CM, Castro Filho JE, Rejowski RF, Trigo-Rocha FE, Bruschini H, Barros Filho TE, Srougi M.

Int Braz J Urol. 2010 Jan-Feb;36(1):66-74.

3.

Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.

Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, Marque P, Rischmann P, Gamé X.

BJU Int. 2010 Dec;106(11):1677-80. doi: 10.1111/j.1464-410X.2010.09435.x.

4.

Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.

Alvares RA, Silva JA, Barboza AL, Monteiro RT.

Int Braz J Urol. 2010 Nov-Dec;36(6):732-7.

5.

Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.

Harris MA, Harding C, Fulford S, Whiteway J.

BJU Int. 2011 Apr;107(7):1165; author reply 1165. doi: 10.1111/j.1464-410X.2011.10216.x. No abstract available.

6.
7.

Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

Cruz F, Nitti V.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630. Review.

PMID:
25042140
8.

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S.

J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004. Epub 2011 Apr 16.

PMID:
21497851
9.
10.

Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.

Abdel-Meguid TA.

J Urol. 2010 Dec;184(6):2423-8. doi: 10.1016/j.juro.2010.08.028. Epub 2010 Oct 16.

PMID:
20952003
11.

Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.

Hikita K, Honda M, Kawamoto B, Panagiota T, Inoue S, Hinata N, Muraoka K, Takenaka A.

Int J Urol. 2013 Jan;20(1):94-9. doi: 10.1111/j.1442-2042.2012.03218.x. Epub 2012 Nov 6.

12.

Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.

Corcos J, Biardeau X, Aharony S.

World J Urol. 2015 Jun;33(6):899-901. No abstract available.

PMID:
26217823
13.

Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).

Nambiar A, Lucas M.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S21-5. doi: 10.1002/nau.22631. Review.

PMID:
25042139
14.

Botulinum toxin a for idiopathic detrusor overactivity.

Lie KY, Wong MY, Ng LG.

Ann Acad Med Singapore. 2010 Sep;39(9):714-5.

15.

Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.

Datta SN, Roosen A, Pullen A, Popat R, Rosenbaum TP, Elneil S, Dasgupta P, Fowler CJ, Apostolidis A.

J Urol. 2010 Dec;184(6):2578-85. doi: 10.1016/j.juro.2010.07.034. Epub 2010 Oct 28.

PMID:
21030043
16.

Re: botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.

Wein AJ.

J Urol. 2014 May;191(5):1340-1. doi: 10.1016/j.juro.2014.02.032. Epub 2014 Feb 20. No abstract available.

PMID:
24745503
17.

Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P.

Neurourol Urodyn. 2013 Mar;32(3):242-9. doi: 10.1002/nau.22293. Epub 2012 Sep 10.

PMID:
22965657
18.

Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.

Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, Apostolidis A, Hamid R, Dasgupta P, Kessler TM, Fowler CJ.

J Urol. 2011 Apr;185(4):1344-9. doi: 10.1016/j.juro.2010.12.002. Epub 2011 Feb 22.

PMID:
21334639
20.

Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.

Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.

Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28. Review.

PMID:
23632286

Supplemental Content

Support Center